Of note, the anti-tumor effects of type I IFN, still exploited today in several cancers, were shown to depend on host NK cells, and mice in which IFNAR was blocked by monoclonal antibody failed to reject even highly immunogenic tumors, as opposed to mice treated with control antibody, who all rejected the immunogenic tumor challenge [82]. The gene discussed is IFNAR1; the disease is neoplasm.